Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference
Rhea-AI Summary
Clene (Nasdaq: CLNN) announced management will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference and host 1x1 investor meetings on December 4, 2025 in New York, New York. Meetings are by appointment via Benchmark representatives. The company and its subsidiary Clene Nanomedicine focus on mitochondrial health and neuronal protection for neurodegenerative diseases, including ALS and MS.
Positive
- None.
Negative
- None.
News Market Reaction 6 Alerts
On the day this news was published, CLNN gained 1.27%, reflecting a mild positive market reaction. Argus tracked a peak move of +27.1% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $102M at that time.
Data tracked by StockTitan Argus on the day of publication.
SALT LAKE CITY, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference by hosting 1x1 investor meetings.
Conference Details
Date: December 4, 2025
Location: New York, New York
Format: 1x1 meetings (contact your Benchmark Representative)
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When will Clene (CLNN) meet investors at the Benchmark conference?
How can investors schedule a 1x1 meeting with Clene (CLNN) at the Benchmark conference?
Where is the Benchmark 14th Annual Discovery One-on-One Investor Conference taking place for Clene (CLNN)?
What will Clene (CLNN) management discuss at the Benchmark investor meetings?
Is the Clene (CLNN) presentation at Benchmark open to the public or by appointment only?
Which Clene entity is attending the Benchmark conference under the CLNN ticker?
